Study
| Open-label, single-center, phase II study |
| Previously untreated non-GCB DLBCL |
| 60 patients |
| Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RLI) after two cycles, 6 cycles RLI + Standart CT |
Efficacy
| ORR after two cycles of RLI: 86.2% |
| CR at end of RLI-chemo: 94.5% |
| 2-year-PFS and -OS: 91.3% and 96.6% |
Safety
| Any grade AEs: Nausea (85%), peripheral sensory neuropathy (83%), diarrhea (78%), mucositis (75%) |
| Grade ≥3 AEs neutropenia 53%, thrombocytopenia 47%, anemia 38% |
J Clin Oncol. 2022 Aug 11.
http://doi.org/10.1200/jco.22.00597
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
